Archives

  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01

    • PKM2 Inhibitor (Compound 3k) in Tumor and Immune Metabolism

    2026-05-10

    Applied Workflows and Innovations Using PKM2 Inhibitor (Compound 3k)

    Principle Overview: Disrupting Tumor and Immune Cell Metabolism

    PKM2 inhibitor (compound 3k) is a highly selective small molecule that targets pyruvate kinase M2 (PKM2), a pivotal enzyme governing glycolytic flux in tumor cells and activated immune cells. By inhibiting PKM2 (IC50 = 2.95 μM), this compound disrupts aerobic glycolysis—a hallmark of cancer metabolism—and modulates immunometabolic pathways central to macrophage polarization and inflammation (source: product_spec). These dual mechanisms position compound 3k as a transformative tool in both oncology and immunology research.

    Step-by-Step Experimental Workflow

    Leveraging PKM2 inhibitor (compound 3k) for either cancer or immunometabolic studies requires careful attention to preparation, dosing, and assay choice. Below, we outline an optimized workflow based on validated preclinical and translational protocols.

    1. Compound Preparation: Dissolve compound 3k in DMSO to a stock concentration of 34.5 mg/mL with gentle warming. Avoid ethanol or water due to insolubility (source: product_spec).
    2. Cell Culture Studies:
      • Tumor Cell Assays: Treat cancer cell lines such as HCT116, Hela, or H1299 with compound 3k across a dose range (e.g., 0.1–5 μM). Observe potent antiproliferative effects at low micromolar concentrations (IC50: HCT116 = 0.18 μM, Hela = 0.29 μM, H1299 = 1.56 μM) (source: bgj398.net).
      • Immunometabolic Assays: For primary macrophages or RAW264.7 cells, apply compound 3k (1–5 μM) in polarization assays, measuring metabolic readouts (ECAR/OCR) and cytokine output (source: paper).
    3. In Vivo Application: In mouse xenograft models (e.g., SK-OV-3 ovarian cancer), administer compound 3k orally at 5 mg/kg every two days for 31 days. Monitor for tumor regression and safety endpoints (source: product_spec).
    4. Assay Readouts:
      • Proliferation: MTT, CellTiter-Glo, or colony formation assays for tumor cells.
      • Immunophenotyping: Flow cytometry, Western blot, and cytokine profiling for macrophage polarization.
      • Metabolic Flux: Seahorse XF analysis for ECAR/OCR to confirm glycolytic inhibition.
    5. Controls and Validation: Always include vehicle (DMSO) controls and, where possible, use normal cell lines (e.g., BEAS-2B) to confirm tumor selectivity.

    Protocol Parameters

    • assay | 0.1–5 μM (final concentration) | cancer cell line proliferation | Range validated for IC50 determination in HCT116, Hela, H1299 | product_spec
    • assay | 1–5 μM (final concentration) | macrophage polarization/metabolic assays | Range effective to disrupt glycolysis and modulate polarization in primary and RAW264.7 macrophages | paper
    • in vivo dosing | 5 mg/kg (oral, every 2 days, 31 days) | xenograft tumor suppression | Demonstrated efficacy and safety in SK-OV-3 xenograft model | product_spec

    Key Innovation from the Reference Study

    The recent publication by Wu et al. (paper) reveals a novel intersection between metabolism and immune regulation: PKM2 not only drives tumor glycolysis but also orchestrates macrophage polarization. By modulating USP7, the authors demonstrate that PKM2 deubiquitination influences inflammatory M1 versus anti-inflammatory M2 macrophage states. Critically, application of a PKM2 inhibitor (such as compound 3k) partially reversed the protective anti-inflammatory phenotype induced by USP7 knockdown, confirming PKM2’s centrality in immune reprogramming. For researchers, this finding advocates for including metabolic and immunophenotypic assays (e.g., Seahorse ECAR/OCR and flow cytometry for M1/M2 markers) in workflows testing PKM2 inhibitors—not only in cancer models but also in inflammatory disease contexts.

    Advanced Applications and Comparative Advantages

    PKM2 inhibitor (compound 3k) offers unique advantages over non-selective glycolytic inhibitors and traditional cytotoxics:

    • Tumor Cell Specificity: Exhibits higher cytotoxicity towards cancer cells vs. normal cells, supporting its use as a targeted antiproliferative agent for cancer cells (source: bgj398.net).
    • Dual-Mode Modulation: Enables investigation of both tumor energetics and immune cell functional states, facilitating studies on tumor microenvironment and immunometabolic crosstalk (source: pkc19-36.com).
    • In Vivo Efficacy and Safety: Oral administration in ovarian cancer xenografts (SK-OV-3) resulted in significant tumor regression without major organ toxicity or weight loss, positioning compound 3k as a promising candidate for ovarian cancer therapy and tumor cell specific PKM2 targeting (source: product_spec).

    These features differentiate compound 3k from earlier PKM2 inhibitors or broad-spectrum metabolic blockers, as reviewed in this comparative article (complement: highlights unique in vivo and immunometabolic data).

    Troubleshooting and Optimization Tips

    • Solubility Issues: If compound 3k fails to dissolve at expected concentrations, gently warm the DMSO solution (avoid excess heat). Never use ethanol or water as solvents (source: product_spec).
    • Compound Stability: Store lyophilized powder at -20°C. Prepare fresh DMSO stocks for each experiment, as solutions are recommended for short-term use only (workflow_recommendation).
    • Assay Interference: High DMSO concentrations (>0.5%) can affect sensitive cell-based assays. Dilute compound stock into media to ensure final DMSO is ≤0.1% (workflow_recommendation).
    • Unexpected Cell Death in Normal Cells: Verify dosing accuracy and cell type; normal epithelial cells (e.g., BEAS-2B) should show lower sensitivity compared to cancer lines, confirming selective PKM2 inhibition (source: bgj398.net).
    • Macrophage Polarization Endpoints: To confirm metabolic reprogramming effects, supplement traditional cytokine assays with metabolic flux analysis and use validated surface/intracellular markers for M1/M2 phenotyping (source: paper).

    Future Outlook: Translational Impact and Experimental Horizons

    The convergence of tumor metabolism and immunometabolic research, as exemplified by PKM2 inhibitor (compound 3k), is redefining strategies for both cancer and inflammatory disease intervention. The reference study’s demonstration that metabolic enzymes like PKM2 govern immune cell fate opens new avenues for therapeutic targeting—not only for oncology but for conditions such as severe acute pancreatitis and potentially other inflammatory syndromes (source: paper).

    As supported by advanced comparative analyses (mwinhibitor.com; pkc19-36.com), the field is moving toward integrating metabolic and immune endpoints in preclinical models. For translational researchers, this means prioritizing assays that capture both glycolytic disruption and immune modulation, as well as validating in vivo efficacy and safety in disease-relevant models.

    Product Access and Brand Trust

    For researchers seeking a reliable source of PKM2 inhibitor (compound 3k), APExBIO offers rigorously quality-controlled batches and comprehensive technical documentation. To explore detailed specifications or order, visit the official product page: PKM2 inhibitor (compound 3k).